Citations

Clear

14 citation(s) found for "Simmons, David".

ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.
Oxnard, Geoffrey R. , Mandrekar, Sumithra J. , Malik, Shakun , Mooney, Margaret , Abrams, Jeffrey S. , Jänne, Pasi A. , Gerber, David E. , Dahlberg, Suzanne E. , Li, Tianhong , Ramalingam, Suresh S. , Vokes, Everett E. , Govindan, Ramaswamy

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS7583-TPS7583

10.1200/jco.2015.33.15_suppl.tps7583 Get It

Lessons learned from lifestyle prevention trials in gestational diabetes mellitus
Egan, Aoife M. , Simmons, David , Egan, A M , Simmons, D

Mayo Clinic

Diabetic Medicine | June 25, 2018 | Volume: 36 | Issue: 2 | Pages: 142-150

10.1111/dme.13772 | PMID 29939439 Get It

AbstractGestational diabetes mellitus (GDM) is associated with an increased risk of adverse outcomes for mother and infant both at birth and later in life. A large body of evidence is now available relating to antenatal prevention of GDM. Overall, despite some individual trials of a variety of lifestyle interventions revealing benefit, many more have shown no effect from the second trimester onwards, even with significant gestational weight gain limitation. At‐risk women often seem reluctant to engage in lifestyle changes and frequently cannot adhere to recommended interventions even within a clinical trial setting. Many trials have not considered the heterogeneity of diabetes first discovered in pregnancy, something of importance into the future. Future work should focus on designing interventions acceptable to the population at risk, whether those taking place before or during the first trimester of pregnancy are effective, and whether greater individualization can identify those women most likely to benefit.
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer
Govindan, Ramaswamy , Mandrekar, Sumithra J. , Gerber, David E. , Oxnard, Geoffrey R. , Dahlberg, Suzanne E. , Chaft, Jamie E. , Malik, Shakun , Mooney, Margaret , Abrams, Jeffrey S. , Jänne, Pasi A. , Gandara, David R. , Ramalingam, Suresh S. , Vokes, Everett E. , Gandara, David , Gerber, David E , Govindan, Ramaswamy

Mayo Clinic

Clinical Cancer Research | December 15, 2015 | Volume: 21 | Issue: 24 | Pages: 5439-5444

10.1158/1078-0432.ccr-15-0354 | PMID 26672084 Get It

Abstract The treatment of patients with metastatic non–small cell lung cancer (NSCLC) is slowly evolving from empirical cytotoxic chemotherapy to personalized treatment based on specific molecular alterations. Despite this 10-year evolution, targeted therapies have not been studied adequately in patients with resected NSCLC who have clearly defined actionable mutations. The advent of next-generation sequencing has now made it possible to characterize genomic alterations in unprecedented detail. The efforts begun by The Cancer Genome Atlas project to understand the complexities of the genomic landscape of lung cancer will be supplemented further by studying a large number of tumor specimens. The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) is an NCI-sponsored national clinical trials network (NCTN) initiative to address the needs to refine therapy for early-stage NSCLC. This program will screen several thousand patients with operable lung adenocarcinoma to determine whether their tumors contain specific molecular alterations [epidermal growth factor receptor mutation (EGFR) and anaplastic lymphoma kinase rearrangement (ALK)], making them eligible for treatment trials that target these alterations. Patients with EGFR mutation or ALK gene rearrangement in their tumor will be randomized to placebo versus erlotinib or crizotinib, respectively, after completion of their standard adjuvant therapy. ALCHEMIST will also contain a large discovery component that will provide an opportunity to incorporate genomic studies to fully understand the clonal architecture, clonal evolution, and mechanisms of resistance to therapy. In this review, we describe the concept, rationale, and outline of ALCHEMIST and the plan for genomic studies in patients with lung adenocarcinoma. Clin Cancer Res; 21(24); 5439–44. ©2015 AACR.
Hypothalamic Distribution of Somatostatin mRNA Expressing Neurones Relative to Pubertal and Adult Changes in Pulsatile Growth Hormone Secretion in Mice
Tan, H. Y. , Huang, Lili , Simmons, David G. , Veldhuis, Johannes D. , Steyn, Frederik J. , Chen, Chen , Steyn, F J , Chen, C

Mayo Clinic

Journal of Neuroendocrinology | July 15, 2013 | Volume: 25 | Issue: 10 | Pages: 910-919

10.1111/jne.12078 | PMID 23855876 Get It

The age‐associated decline in growth hormone (GH) secretion may be a consequence of the reduction in the number of GH‐releasing hormone (GHRH) positive neurones. However, it remains unclear whether an alteration in the number or distribution of somatostatin (SST) neurones contributes to this change. In the present study, we characterised the role of SST in modulating the change in pulsatile GH secretion in male C57Bl/6J mice throughout puberty and into early adulthood. We assessed pulsatile GH secretion in mice at 4, 8 and 16 weeks of age. These ages correspond to early pubertal, early adulthood and adulthood, respectively. We show an elevation in peak, total and pulsatile GH secretion coinciding with periods of rapid linear growth. Using in situ hybridisation and morphometric methods, we mapped the distribution of Sst mRNA expression within the mouse brain relative to this change in pulsatile GH secretion. The results obtained show that altered pulsatile GH secretion in male mice from 4–16 weeks of age does not coincide with a significant change in the number of Sst mRNA expressing neurones or an abundance of Sst mRNA expression throughout the arcuate nucleus (ARC) and periventricular nucleus (PeV). Rather, we observed a progressive decline in Sst mRNA expressing neurones within subnuclei of the paraventricular nucleus at this time. We conclude that structural changes in Sst expression within the PeV and ARC may not reflect the observed decline in pulsatile GH secretion in mice from puberty into early adulthood.